GOVX
GeoVax Labs, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.21
P/S
0.38
EV/EBITDA
0.15
DCF Value
$18.28
FCF Yield
-1913.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.3%
Operating Margin
-761.6%
Net Margin
-754.7%
ROE
-489.7%
ROA
-376.0%
ROIC
-520.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $-6.3M | $-7.75 |
| Q2 2025 | $852.3K | $-5.4M | $-8.75 |
| Q1 2025 | $1.6M | $-5.4M | $-11.25 |
| Q4 2024 | $864.4K | $-8.3M | $-19.50 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
3.81
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.